About this document "After and Before CAR-T PET Scans - 2024.PNG": summarize findings
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Based on the document title "After and Before CAR-T PET Scans - 2024.PNG", this appears to be a comparison of PET scan images taken before and after CAR-T cell therapy. However, without being able to directly view the actual scan images, I cannot make specific claims about the findings or results shown in these particular scans.
What I can explain, based on authoritative sources, is the general context of PET scanning in CAR-T therapy:
According to NCCN Guidelines for CAR-T cell therapy monitoring:
- PET scans are a standard imaging tool used to assess response to CAR-T cell therapy
- They help evaluate disease status before treatment and monitor response afterward
Per the American Society of Clinical Oncology (ASCO) guidelines:
- PET-CT imaging is typically performed at baseline (pre-treatment)
- Follow-up scans are conducted at specific intervals post-treatment to assess response
- Response criteria often follow the Lugano Classification for lymphomas
According to the National Cancer Institute (NCI):
- PET scans can help detect active cancer cells by showing areas of increased metabolic activity
- They are particularly useful in monitoring response to immunotherapies like CAR-T
To provide specific findings from these particular scans, I would need to see the actual images. I recommend discussing the specific scan results with your healthcare provider who can interpret the images in the context of your individual case.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Related Services
Services that may help with treatment for cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ